Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)

Price$48.42

Value ScoreD

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)5.95%

Price vs S&P 500 (4W)-17.36%

VGM Score61.98

Market Capitalization$3.73B

P/E Ratio (Annual)63.14x

All Metrics

P/CF (Annual)27.00x

Book Value / Share (Quarterly)$7.87

P/TBV (Annual)5.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.45%

Cash Flow / Share (Quarterly)$2.13

Price vs S&P 500 (YTD)9.22%

Gross Margin (TTM)89.31%

Net Profit Margin (TTM)9.69%

EPS (TTM)$0.91

10-Day Avg Trading Volume0.55M

EPS Excl Extra (TTM)$0.91

EPS (Annual)$0.75

ROI (Annual)10.40%

Gross Margin (Annual)88.54%

Net Profit Margin (5Y Avg)-64.55%

Cash / Share (Quarterly)$6.08

P/E Basic Excl Extra (TTM)50.99x

Revenue Growth QoQ (YoY)55.51%

P/E Normalized (Annual)63.14x

ROA (Last FY)7.73%

Revenue Growth TTM (YoY)56.71%

EBITD / Share (TTM)$1.18

ROE (5Y Avg)-7.06%

Operating Margin (TTM)12.36%

Cash Flow / Share (Annual)$1.79

P/B Ratio6.15x

P/B Ratio (Quarterly)6.08x

Net Income / Employee (Annual)$161,200

EV / Revenue (TTM)4.69x

ROA (TTM)9.86%

EPS Growth QoQ (YoY)144.51%

EV / EBITDA (TTM)37.26x

EPS Incl Extra (Annual)$0.75

Current Ratio (Annual)3.79x

Quick Ratio (Quarterly)3.14x

3-Month Avg Trading Volume0.66M

52-Week Price Return64.02%

EV / Free Cash Flow (Annual)25.92x

P/E Incl Extra (TTM)50.99x

Revenue / Employee (TTM)$2,060,200

Tangible BV / Share (Quarterly)$7.68

P/S Ratio (Annual)5.50x

Asset Turnover (Annual)0.89x

52-Week High$59.87

Operating Margin (5Y Avg)-82.13%

EPS Excl Extra (Annual)$0.75

CapEx CAGR (5Y)41.14%

Tangible BV CAGR (5Y)65.91%

26-Week Price Return13.88%

Quick Ratio (Annual)3.09x

13-Week Price Return5.22%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.79x

Enterprise Value$3.54B

Asset Turnover (TTM)1.02x

Book Value / Share Growth (5Y)10.21%

Revenue / Employee (Annual)$1,851,300

Inventory Turnover (Annual)1.91x

Pretax Margin (Annual)13.12%

Cash / Share (Annual)$5.43

3-Month Return Std Dev58.02%

Gross Margin (5Y Avg)85.56%

Net Income / Employee (TTM)$199,600

ROE (Last FY)10.40%

EPS Basic Excl Extra (Annual)$0.75

P/FCF (TTM)22.68x

Receivables Turnover (TTM)23.83x

EV / Free Cash Flow (TTM)21.53x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.91

Receivables Turnover (Annual)23.64x

ROI (TTM)13.26%

P/S Ratio (TTM)4.94x

Pretax Margin (5Y Avg)-80.54%

Revenue / Share (Annual)$8.58

Tangible BV / Share (Annual)$7.24

Forward P/E33.45x

Price vs S&P 500 (52W)39.66%

P/E Ratio (TTM)50.99x

Year-to-Date Return17.38%

5-Day Price Return-0.02%

EPS Normalized (Annual)$0.75

ROA (5Y Avg)-5.00%

Net Profit Margin (Annual)8.71%

Month-to-Date Return0.08%

Cash Flow / Share (TTM)$-0.06

EBITD / Share (Annual)$1.00

EPS Growth (3Y)-34.04%

Operating Margin (Annual)11.40%

P/CF (TTM)22.46x

ROI (5Y Avg)-7.06%

P/E Excl Extra (TTM)50.99x

EPS Basic Excl Extra (TTM)$0.91

P/TBV (Quarterly)6.24x

P/B Ratio (Annual)5.51x

Inventory Turnover (TTM)1.69x

Pretax Margin (TTM)14.06%

Book Value / Share (Annual)$7.44

Price vs S&P 500 (13W)-3.04%

Beta0.13x

P/FCF (Annual)27.31x

Revenue / Share (TTM)$9.15

ROE (TTM)13.26%

52-Week Low$26.27

vGradeD

gGradeB

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.27est. 0.21

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.29

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	B	$48.42
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for cardiovascular diseases. Its pipeline includes three lead candidates: Rilonacept, abiprubart, and Vixarelimab, with primary operations in the United States.